Candel Therapeutics (CADL) Stock: Buy, Sell, or Hold?
CADL - Candel Therapeutics, Inc. Common Stock
$11.02
-0.10 (-0.90%)
▼
5d:
-9.45%
30d:
-9.38%
90d:
+38.27%
HOLD
MODERATE Confidence
Analysis Updated: Sep 16, 2026 12:00 AM ET
Earnings: Aug 13, 2026
0d
Get Alerted When CADL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: CADL shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: CADL shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
In-depth Analysis How we analyze
Valuation Analysis: CADL is currently trading at $11.02, which is considered slightly low relative to its 30-day fair value range of $11.18 to $13.24. From a valuation perspective, the stock is trading at a discount (Forward PE: -17.6) compared to its historical average (40.5). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, CADL is in a strong uptrend. Immediate support is located at $9.86, while resistance sits at $13.41.
Market Sentiment: The stock scores a mixed 43/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $21.00 (+90.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, CADL is in a strong uptrend. Immediate support is located at $9.86, while resistance sits at $13.41.
Market Sentiment: The stock scores a mixed 43/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $21.00 (+90.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$11.18 -
$13.24
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
84.3%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (43/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 90.6% below Wall St target ($21.00)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- NEUTRAL: Bottoming setup forming (43/100) — watch for confirmation
- CAUTION: 5-day price weakness (-9.4%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$11.18 -
$13.24
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$9.86
Resistance Level
$13.41
Current Trend
Strong Uptrend
Technical data as of
Sep 16, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-17.63
Wall Street Target
$21.00
(+90.6%)
PE vs Historical
-17.6 vs 40.5
CHEAP
Share & Embed Analysis
Last updated: September 17, 2026 12:43 AM ET
Data refreshes hourly during market hours. Next update: 1:43 AM
Data refreshes hourly during market hours. Next update: 1:43 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CADL showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$84 | 51 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$27 | 50 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 47 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$92 | 50 HOLD |
